<DOC>
	<DOCNO>NCT00724386</DOCNO>
	<brief_summary>The goal study determine feasibility base toxicity response rate give paclitaxel weekly concomitant every-other week radiotherapy limit skin toxicity . This study also seek determine maximally tolerate dose Navelbine add combination follow Filgrastim dose-limiting toxicity regimen .</brief_summary>
	<brief_title>Concomitant Chemoradiotherapy With Weekly Paclitaxel Vinorelbine Granulocyte Colony Stimulating Factor ( GCSF ) Support Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma male female breast ( male female ) gross , uncontrolled , unresectable breast and/or chest wall disease include : 1. patient locally advance unresectable stage IIIa IIIb ; 2. patient locally recurrent ( include locoregional lymph node ) disease curative surgery think possible 3. patient metastatic disease AND uncontrolled locoregional disease eligible . Prior chemotherapy allow , except nitrosoureas mitomycin chemotherapy high dose chemotherapy marrow stem cell rescue . Prior palliative radiation sit metastasis allow ( i.e . bone , brain , lung ) 4 week since prior treatment ( exclude hormonal therapy ) . Concurrent hormonal therapy allow . Aged 18 year old CALGB performance status 0 2 Life expectance least 12 week Initial Laboratory Data : ANC Count &gt; 1500/mm3 Platelet Count &gt; 100,000/mm3 Creatine ≤ 2.0 mg/dl Bilirubin ≤ 1.5 mg/dl ALT ( SGPT ) ≤ 3 time upper limit normal Signed inform consent Prior breast chest wall radiation allow unless propose site radiation port overlap prior port Subjects must pregnant ( female able child must negative pregnancy test agree use adequate contraception ) Patients documented hypersensitivity E.coli derive protein exclude . No serious medical condition uncontrolled infection opinion investigator place patient undue risk study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>